

SenseCare-Lung Pro enables faster-automated diagnosis of lung diseases

November 4, 2020 | News

SenseTime awarded CE Mark for SenseCare-Lung Pro, an AI-empowered software solution to analyze CT image of lungs



SenseTime, the world-leading artificial intelligence (AI) company, on 4 Nov 2020 announced its AI-empowered software solution, SenseCare-Lung Pro, has been awarded the CE mark to meet the safety and performance requirements demanded in the European Economic Area (EEA). The software enables faster and more automated diagnosis of lung diseases including COVID-19 infections based on CT image analysis.

The CE certification of SenseCare-Lung Pro ensures that the software can be commercialised in the EU market under the European Union Medical Device Regulation (MDR), a new regulation issued in response to the development of the medical device industry with higher requirements for the clinical evaluation and product testing before the device is approved for use in the market. The milestone demonstrates the solution's ability to analyze lung diseases safely and effectively.

Based on SenseTime's deep learning technologies, SenseCare-Lung Pro software improves the efficiency and accuracy of the diagnostic procedures for doctors in identifying lung cancers and pneumonia. Its AI capabilities mean it can automatically detect abnormalities of lung nodules and pneumonia, like COVID-19. It provides comprehensive analysis such as lesion classification, risk evaluation, quantification, and general structured reports.

SenseCare-Lung Pro is one of several applications in SenseTime's SenseCare Smart Health Platform – an AI-powered platform which offers an array of healthcare applications for over 13 organs and body parts, covering chest, cardiovascular, liver, pathology, orthopedics and radiotherapy. It can assist doctors throughout the clinical process, from diagnosis, 3D surgery planning to rehabilitation tracking to meet the demands of various departments including radiology, pathology, cardiology, orthopedic, surgery, radiotherapy, etc.

SenseTime have extended presences in markets including Hong Kong, Mainland China, Japan, Singapore, South Korea, Indonesia, Saudi Arabia, the United Arab Emirates, Taiwan and Macau.